Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

28,119 26,813

Interest income and

other, net 864 1,189 2,855 3,402

Net income (loss) (2) $12,307 $(6,259) $(1,372) (19,142)

Net loss per share,

basic and diluted (2) $0.43 $(0.22) $(0.05) $(0.67)

Share used in

calculating net loss

per share, basic and

diluted 28,651 28,562 28,637 28,489

(1) Includes $77 and ($1,897) as additional (reduction in) research and

development expense, which represents an estimate of the net payable

due to (reimbursement by) Novartis of ANA975 research and development

costs for the three months ended September 30, 2007 and 2006,

respectively. Includes ($514) and ($3,423) as an offset in research

and development expense, which represents an estimate of the net

reimbursement by Novartis of ANA975 research and development costs for

the nine months ended September 30, 2007 and 2006, respectively.

(2) Includes non-cash operating expenses of $1,392 and $2,010 determined

in accordance with Statement of Financial Accounts Standards No.

123(R), "Share-Based Payment" (SFAS No. 123(R)) or approximately $0.05

and $0.07 effect on basic and diluted net income (loss) per common

share for the three months ended September 30, 2007 and 2006,

respectively. Research and development expense and general and

administrative expense includes $969 and $423 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the three

months ended September 30, 2007. Includes non-cash operating expenses

of $3,502 and $4,951 determined in accordance with Financial Accounts

Standards Board Statement 123(R), "Share-Based Payment" or

approximately $0.12 and $0.17 effect on basic and diluted net l
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Cereal ... food industries will gather October 5–8, 2014, for ... Rhode Island Convention Center in Providence, Rhode Island. ... the work of food scientists, chemists, microbiologists, nutritionists, ... and food production management. To date, 1,000 attendees ...
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2
... , CHICAGO, Aug. 26 Ajinomoto ... by adding food product development capabilities. The Application Center North ... , , The ACNA mission is to develop ... food technology applications will be the initial focus of the Center: ...
... , SAN MARINO, Calif., Aug. 26 Viral ... for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in ... August 25 and August 26, and an article published on ... Viral Genetics, Inc. (VRAL)," on August 25. , , ...
... , , , ... SGP ), today announced that the European Medicines Agency ... Application (MAA) for a fixed-dose combination of mometasone furoate and ... 12 years of age and older. The company also ...
Cached Biology Technology:Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 2Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 3Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
(Date:9/18/2014)... The global cycles of carbon and nitrogen comprise ... human and environmental systems have caused imbalances and ... greenhouse gases (GHGs). Increased GHGs result in climate ... terrestrial ecosystems, oceans and the atmosphere. Understanding these ... exciting branch of environmental science during the past ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2
... improve blood flow in diseased arteries, reducing the risk of ... published today reveals. , The finding is a significant development ... Care, hopes to use the drug as part of a ... Schmidt, Director of the Centre for Vascular Health and his ...
... women with serious depression and healthy women in a ... , The study adds further evidence that depression has ... specifically in the endogenous opioid system that is a ... system. The findings also show significant variation between individuals ...
... have a significantly increased risk of having autism spectrum ... 30 years, according to an article in the September ... JAMA/Archives journals. , Autism is characterized by social and ... background information in the article. Autism and related ...
Cached Biology News:Heart smart: new drug improves blood flow 2New brain-chemistry differences found in depressed women 2New brain-chemistry differences found in depressed women 3Older fathers more likely to have autistic children 2
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
...
Biology Products: